GGHC
COGT icon

Gilder Gagnon Howe & Co’s Cogent Biosciences COGT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.01M Sell
52,163
-1,112
-2% -$41.1K 0.02% 200
2025
Q4 		$1.89M Buy
+53,275
New +$1.5M 0.02% 198

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Gilder Gagnon Howe & Co's COGT Position: Q1 2026 in Review

Gilder Gagnon Howe & Co reduced its Cogent Biosciences (COGT) stake by 2.1% in Q1 2026, selling an estimated $41.1K and leaving 52,163 shares worth $2.01M. The position accounts for 0.02% of the portfolio, ranked #200.

Gilder Gagnon Howe & Co first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Gilder Gagnon Howe & Co held 52,163 shares of Cogent Biosciences worth $2.01M as of Q1 2026.
  • Gilder Gagnon Howe & Co sold 1,112 Cogent Biosciences shares in Q1 2026, an estimated $41.1K.
  • Cogent Biosciences made up 0.02% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #200 holding.
  • Gilder Gagnon Howe & Co first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.